Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pimecrolimus 0.3% ophthalmic ointment
- Development stage
- Unknown
- Lead developer
- Viatris
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
MR-139 is a 0.3% ophthalmic ointment formulation of pimecrolimus, a calcineurin inhibitor. It was developed for the treatment of blepharitis, specifically targeting inflammation and debris at the eyelid margins. The primary mechanism of action is inhibition of calcineurin, leading to reduced T-cell activation and decreased cytokine release, which suppresses the inflammatory response. The ointment is self-administered to the eyelids twice daily.
- Other names
- pimecrolimus ointment for blepharitisMR-139 ointmentMR139 ointmentMR 139 ointment
02
Targets
CN (Calcineurin)FKBP1A
Beyond the preview
Go deeper on pimecrolimus 0.3% ophthalmic ointment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pimecrolimus 0.3% ophthalmic ointment.